<DOC>
	<DOCNO>NCT02607774</DOCNO>
	<brief_summary>To determine whether secukinumab alter activity cytochrome P450 ( CYP ) 3A4 use midazolam probe substrate patient moderate-to-severe plaque psoriasis .</brief_summary>
	<brief_title>Investigate Effect Secukinumab PK Midazolam Patients With Mod Sev Plaque Psoriasis</brief_title>
	<detailed_description>This open-label , confirmatory study investigate potential disease-drug-drug interaction secukinumab midazolam male female patient moderate-to-severe plaque psoriasis . A total approximately 25 patient require obtain least 20 completers study Patients meet eligibility criterion screen , baseline assessment day ( within 1 week prior start secukinumab ) full midazolam PK profile single oral dose 5 mg assess collect blood 12 hour postdose period . On Day 1 ( Week 0 ) , Day 8 ( Week 1 ) , Day 15 ( Week 2 ) , Day 22 ( Week 3 ) Day 29 ( Week 4 ) patient receive 300 mg s.c. secukinumab ( 2 injection 150 mg s.c. ) . On Day 8 Day 36 ( Week 5 ) , patient receive additional single dose 5 mg oral midazolam ( total 3 single dos ) . The midazolam PK profile assess 12 hour postdose period . On day midazolam PK profile assess , sample collect analyzed circulate IL-6 , inflammatory panel ( collect screening , baseline pre-dose Day 1 ) , total IL-17A ( follow initiation secukinumab treatment ) , hsCRP 4-beta-hydroxycholesterol ( exploratory endogenous phenotyping marker CYP3A activity ) . There extended treatment period patient receive secukinumab 300 mg s.c. Weeks 8 , 12 , 16 , 20 24 . Then follow-up period 12 week follow last dose administer Week 24 . Visits Weeks 28 , 32 36 .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Moderate severe plaque psoriasis define baseline : PASI score 12 great IGA mod 2011 score 3 great ( base scale 0 4 ) Body Surface Area ( BSA ) affect plaquetype psoriasis 10 % great . Chronic plaquetype psoriasis consider inadequately control : topical treatment and/or ; phototherapy and/or previous systemic therapy Men woman least 18 year age old time screen . Forms psoriasis chronic plaquetype Pregnant nursing ( lactate ) woman , History ongoing , chronic recurrent infectious disease , evidence tuberculosis infection . Subjects know history hypersensitivity midazolam</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Plaque psoriasis</keyword>
	<keyword>disease-drug-drug-interaction</keyword>
	<keyword>midazolam</keyword>
	<keyword>secukinumab</keyword>
</DOC>